Tolerability of anti-tuberculosis treatment and HIV serostatus

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 11, 2007, Pages 1203-1209

  Lanternier, Fanny ^a   Dalban, C ^b   Perez, L ^a   Bricaire, F ^a   Costagliola, D ^b   Caumes, E ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Drug tolerability; HIV; Paradoxical reaction; Tuberculosis

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; TENOFOVIR;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 36349035163     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Colebunders R, Lambert M L. Management of co-infection with HIV and TB. BMJ 2002; 324: 802-803.
2. Murray J, Sonnenberg P, Shearer S C, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740.
3. Burman W J, Jones B E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12.
4. Narita M, Ashkin D, Hollender E S, Pitchenik A E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-161.
5. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
6. Dean G L, Edwards S G, Ives N J, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83.
7. el-Sadr W M, Perlman D C, Matts J P, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26: 1148-1158.
8. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030.
9. Small P M, Schecter G F, Goodman P C, Sande M A, Chaisson R E, Hopewell P C. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
10. Iborra C, Cambau E, Lecomte C, Grosset J, Bricaire F, Caumes E. Cutaneous tuberculosis. A study of 4 cases. Ann Dermatol Venereol 1997; 124: 139-143.
11. Ungo J R, Jones D, Ashkin D, et al. Anti-tuberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
12. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.
13. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919.
14. Jones B E, Otaya M, Antoniskis D, et al. A prospective evaluation of anti-tuberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150: 1499-1502.
15. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
16. Dossing M, Wilcke J T, Askgaard D S, Nybo B. Liver injury during anti-tuberculosis treatment: an 11-year study. Tubercle Lung Dis 1996; 77: 335-340.
17. Perriens J H, St Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.